19 unknown. 19 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Unknown 19 |
| Phase 2 | 8 | Unknown 8 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors UCMYM802 Injection - Malignant Mesothelioma, Colorectal Cancer | Phase 1 | Unknown | UTC Therapeutics Inc. | 24 | 2024-03-05 | 2024-07-24 |
| Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Cisplatine Teva® - Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Unknown | Dr Jean Yannis PERENTES | 39 | 2023-11-24 | 2024-02-28 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas APG-5918 - Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer | Phase 1 | Unknown | Ascentage Pharma Group Inc. | 90 | 2022-09-30 | 2022-11-16 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NGM438, Pembrolizumab (KEYTRUDA ®) - Pancreatic Cancer, Breast Cancer | Phase 1 | Unknown | NGM Biopharmaceuticals, Inc | 71 | 2022-05-11 | 2024-04-01 |
| A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. T3011 - Advanced Solid Tumor, Lung Cancer | Phase 1 / Phase 2 | Unknown | ImmVira Pharma Co. Ltd | 74 | 2022-03-01 | 2022-10-28 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies NGM707, NGM707 plus pembrolizumab (KEYTRUDA®) - Mesothelioma, Glioblastoma | Phase 1 / Phase 2 | Unknown | NGM Biopharmaceuticals, Inc | 179 | 2021-06-09 | 2024-10-02 |
| Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity Blood screening, Tissue screening - Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Western Sydney Local Health District | 200 | 2020-12-15 | 2023-06-01 |
| The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma 68Ga-NOTA-exendin-4 - Insulinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 60 | 2020-08-01 | 2023-09-21 |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours SG001 - Advanced Solid Tumours, Cervical Cancer | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 192 | 2019-05-23 | 2021-04-30 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies CAR-T cell immunotherapy - B-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 73 | 2018-03-01 | 2019-12-11 |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) Defactinib, Pembrolizumab - Carcinoma, Non-small-cell Lung, Mesothelioma | Phase 1 / Phase 2 | Unknown | NHS Greater Glasgow and Clyde | 59 | 2017-07-04 | 2018-03-19 |
| A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 IPI-549 (eganelisib), Nivolumab - Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E) | Phase 1 | Unknown | Infinity Pharmaceuticals, Inc. | 219 | 2015-12-01 | 2022-04-04 |
| Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso anti-meso-CAR vector transduced T cells - Malignant Mesothelioma, Pancreatic Cancer | Phase 1 | Unknown | Chinese PLA General Hospital | 20 | 2015-10-01 | 2015-10-20 |
| Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients MesoCancerVac - Mesothelioma | Phase 1 | Unknown | Erasmus Medical Center | 9 | 2015-01-01 | 2015-03-23 |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor | Phase 1 / Phase 2 | Unknown | Ochsner Health System | 250 | 2014-03-01 | 2014-01-17 |
| Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma PA-1-STK ovarian carcinoma vaccine, ganciclovir - Malignant Mesothelioma | Phase 1 | Unknown | Louisiana State University Health Sciences Center in New Orleans | 1997-08-01 | 2013-09-20 | |
| High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma megestrol acetate - Breast Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Unknown | St. Vincent Medical Center - Los Angeles | 1987-12-01 | 2013-11-06 |
Mesothelioma, Malignant (9) · Carcinoma, Non-Small-Cell Lung (8) · Mesothelioma (8) · Ovarian Neoplasms (7) · Stomach Neoplasms (7) · Carcinoma, Renal Cell (5) · Melanoma (5) · Pancreatic Neoplasms (5) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Esophageal Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Hepatocellular (3) · Lymphoma (3)
Neoplasms by Histologic Type (19) · Neoplasms, Glandular and Epithelial (19) · Neoplasms (18) · Neoplasms by Site (18) · Neoplasms, Mesothelial (17) · Lung Diseases (15) · Respiratory Tract Diseases (15) · Respiratory Tract Neoplasms (15) · Thoracic Neoplasms (15) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Lung Neoplasms (13) · Endocrine Gland Neoplasms (12) · Endocrine System Diseases (12)
pembrolizumab (3) · 68Ga-NOTA-exendin-4 (1) · Clinical Trials, Phase II as Topic (1) · Ganciclovir (1) · IPI-549 (1) · Immunotherapy, Adoptive (1) · Megestrol Acetate (1) · Nivolumab (1) · Surgical Procedures, Operative (1) · defactinib (1) · regorafenib (1)
NGM Biopharmaceuticals, Inc (2) · Ascentage Pharma Group Inc. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Chinese PLA General Hospital (1) · Dr Jean Yannis PERENTES (1) · Erasmus Medical Center (1) · First Affiliated Hospital of Fujian Medical University (1) · ImmVira Pharma Co. Ltd (1) · Infinity Pharmaceuticals, Inc. (1) · Institut Bergonié (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Multitude Therapeutics Inc. (1) · NHS Greater Glasgow and Clyde (1) · Ochsner Health System (1) · Shenzhen BinDeBio Ltd. (1)
China (7) · United States (7) · Australia (2) · France (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Caicun Zhou, PhD (1) · Catherine Shannon (1) · Charles L. Wiseman, MD, FACP (1) · Christian Ottensmeier (1) · Dean Fennell (1) · Feng Chi, MD (1) · Golo Ahlenstiel, Professor (1) · Henk C Hoogsteden, MD PhD (1) · Jean-Yannis Perentes (1) · Jeff Evans (1) · Jermaine Coward (1) · Jin Li, PhD (1) · Lin Shen, Doctor (1) · Lingying Wu, PhD (1)
PMID 15764728, PMID 22778767, PMID 23148753, PMID 32234848, PMID 34965951, PMID 34998048, PMID 36104949, PMID 37104017, PMID 37598000, PMID 39214650, PMID 39708537, PMID 40204996, PMID 40579407, PMID 41321671
2015 (1), 2016 (1), 2023 (1)